NASDAQ:MYGN Myriad Genetics Q3 2026 Earnings Date & Estimates $4.31 +0.11 (+2.62%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.30 0.00 (-0.12%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Myriad Genetics is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 2, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Myriad Genetics in Q3 2026Myriad Genetics is expected to post earnings of -$0.16 per share on revenue of $191.48 million. Myriad Genetics last reported on July 30, 2026, posting -$0.25 per share and missing the -$0.0579 consensus estimate. Myriad Genetics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.16Expected Revenue$191.48 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.25 (Missed by -$0.1921)Last Quarter Revenue$190.70 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Myriad Genetics Q3 2026 Earnings FAQ When does Myriad Genetics report Q3 2026 earnings? Myriad Genetics (NASDAQ:MYGN) is scheduled to report Q3 2026 earnings on Monday, November 2, 2026, after market closes. What time is Myriad Genetics' Q3 2026 earnings call? Myriad Genetics' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Myriad Genetics? Analysts expect Myriad Genetics to post earnings of -$0.16 per share for Q3 2026. How much revenue is Myriad Genetics expected to report? The consensus revenue estimate for Myriad Genetics is $191.48 million for Q3 2026. Myriad Genetics Earnings HeadlinesMyriad Genetics Finalizes Separation Agreement With Former CCOOctober 9 at 4:50 PM | tipranks.comMyriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyOctober 8 at 12:30 PM | markets.businessinsider.comWhat’s Elon building now?New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 10 at 1:00 AM | Paradigm Press (Ad)Myriad Genetics (NASDAQ:MYGN) Shares Cross Above Two Hundred Day Moving Average - Here's WhyOctober 7 at 2:01 AM | americanbankingnews.comMyriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split TargetsOctober 4, 2026 | finance.yahoo.comMyriad Genetics (NASDAQ:MYGN) vs. Applied Dna Sciences (NASDAQ:BNBX) Head-To-Head ComparisonSeptember 30, 2026 | americanbankingnews.comSee More Myriad Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Myriad Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Myriad Genetics and other key companies, straight to your email. Email Address About Myriad GeneticsMyriad Genetics (NASDAQ:MYGN) is a molecular diagnostics company that develops and provides genetic tests designed to help healthcare professionals assess disease risk, guide treatment decisions and support patient care. The company serves physicians, hospitals, health systems, biopharmaceutical companies and patients, with a focus on areas including oncology, women’s health and mental health. Its portfolio includes hereditary cancer testing, such as the MyRisk Hereditary Cancer test; tumor profiling and companion diagnostic services used to help inform cancer treatment; prenatal and carrier screening tests, including Prequel and Foresight; and pharmacogenomic testing, including GeneSight, which is intended to help clinicians evaluate how a patient may respond to certain psychiatric medications. Myriad also offers testing and services for other inherited and acquired health conditions. Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has built its business around applying genetic information to personalized medicine. The company primarily serves the United States and also provides products and services through international markets and commercial partnerships, subject to local regulatory and reimbursement requirements.View Myriad Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
